title: Evaluation of aggressive heart rate reduction in patients with stable angina.
abstract: BACKGROUND
  There is a strong correlation between heart rate and myocardial ischemia, cardiovascular diseases, and life expectancy in general; however, heart rate has been neglected as an important risk factor as well as a therapeutic opportunity.
  
  
  OBJECTIVE
  To investigate the effect of aggressive heart rate reduction (50 ⩽ HR ⩽ 60 bpm) on anti-ischemic and anti-anginal efficacy, left ventricular function, exercise tolerance and quality of life in patients with stable coronary artery disease with or without left ventricular dysfunction during 4 months.
  
  
  METHODS
  A total of 159 patients presented with stable CAD without clinical heart failure symptoms were included in a open-label, non-comparative, prospective clinical study between June 2009 to February 2010 in King Abdul Aziz Specialist Hospital, Taif, KSA, Al Hayah National Hospital, Khamis Mushyt, KSA and Critical care department, Cairo University, Egypt. All included patients were, in addition to the ant ischemic treatment, subjected to aggressive heart rate control starting by beta blocker titrated to the maximum dose as tolerated, then Ivabradine added if the target heart rate is not achieved or rate control started by Ivabradine if beta blockers are contraindicated. Exercise treadmill test (ETT) to assess exercise capacity using time to 1 mm ST-segment depression in milliseconds, ejection fraction (EF) assessed by transthoracic echocardiography and frequency of angina attacks and the use of sublingual nitroglycerin per week during the last week were evaluated during a follow-up for 4 months. The patients were divided into two groups, group-I (patients achieved a resting heart rate between 50 and 60 bpm with heart rate reduction treatment) and group-II (patients with resting HR >60 bpm in spite of maximum treatment for heart rate reduction).
  
  
  RESULTS
  The resting heart rate was significantly reduced from 77.98 ± 8.7 at baseline to 60.68 ± 4.34 bpm after 4 months of treatment, P < 0.001. The frequency of angina pectoris attacks had been significantly reduced from 2.14 ± 1.27 to 0.48 ± 0.58 attacks per week, P < 0.001 and the highest significant reduction was observed with group-I. Also, the frequency of use sublingual nitrate therapy was significantly reduced from 1.38 ± 1.1 tablet per week at the last week before the study to 0.12 ± 0.33 tablet per week during the last week after 4 months of treatment, P < 0.001 and the reduction was more significantly with group-I. Exercise treadmill test demonstrated statistically significant increase in the time to 1 mm ST-segment depression from 357.36 ± 66.73 at baseline to 387.96 ± 65.19 ms. after 4 months with P < 0.001. The degree of improvement was significantly higher for group-I (from 358.06 ± 68.81 at baseline to 391.71 ± 69.01 after 4 months with P < 0.001) than that of group-II (from 356.11 ± 64.8 at baseline to 381.27 ± 59.08 after 4 months with P < 0.001). Ejection fraction showed a statistically significant increase from 59.76 ± 6.86 at baseline to 61.04 ± 5.35 after 4 months with P < 0.001.
  
  
  CONCLUSIONS
  This study indicates that heart rate reduction has been associated with an improvement in quality of life in patients with stable coronary artery disease, presenting new opportunities for treatment.
authors: Cardiology Department, Faculty of Medicine, Al Azhar University, Egypt.
authors: Hamdy Abd El
authors: HA
authors: Azeem
authors: El Shazly Abd El
authors: el SA
authors: Khalek
authors: Hazem El
authors: HE
authors: Akabawy
keywords: Heart rate reduction; Stable angina
references: Eur Heart J. 2005 May;26(10):967-74
references: 15774493
references: Scand J Clin Lab Invest. 1981 Jun;41(4):383-9
references: 7313522
references: Am J Cardiol. 1986 Apr 25;57(12):43F-49F
references: 2871745
references: Am J Cardiol. 1973 Apr;31(4):474-9
references: 4692583
references: Circulation. 1976 Sep;54(3):522-3
references: 947585
references: Am Heart J. 1993 Apr;125(4):1148-54
references: 8465742
references: J Am Coll Cardiol. 2005 Jan 18;45(2):252-9
references: 15653024
references: Am J Cardiol. 1990 Mar 1;65(9):547-53
references: 1968702
references: Eur Heart J. 2005 Dec;26(23):2529-36
references: 16214830
references: Eur Heart J. 1986 Apr;7(4):279-88
references: 3720755
references: Cardiovasc Res. 2001 May;50(2):373-8
references: 11334841
references: Circulation. 1978 Dec;58(6):1072-83
references: 709763
references: Am Heart J. 2009 Oct;158(4):e51-7
references: 19781403
references: J Am Coll Cardiol. 1983 Sep;2(3):506-13
references: 6875114
references: J Am Coll Cardiol. 1997 Oct;30(4):1104-6
references: 9316546
references: Hypertension. 1999 Jan;33(1):44-52
references: 9931080
references: Circulation. 2001 Sep 25;104(13):1477-82
references: 11571239
references: Eur Heart J. 2004 Mar;25(5):363-70
references: 15033247
references: Circulation. 2003 Feb 18;107(6):817-23
references: 12591750
references: Drugs. 2004;64(16):1757-65
references: 15301560
references: Lancet. 1999 Jan 2;353(9146):9-13
references: 10023943
references: Am J Hypertens. 2004 Nov;17(11 Pt 1):1005-10
references: 15533725